Media Articles Related to Trelstar Depot (Triptorelin)
Tasquinimod may improve survival in men with metastatic prostate cancer
Source: Bones / Orthopedics News From Medical News Today [2013.11.21]
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Aggressive prostate cancer charted by novel study
Source: Prostate / Prostate Cancer News From Medical News Today [2013.11.20]
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone.
Low-fat diet, omega-3 linked to reduced prostate cancer aggression
Source: Prostate / Prostate Cancer News From Medical News Today [2013.11.20]
A follow-up study reveals that men suffering from prostate cancer who took fish oil supplements alongside a low-fat diet demonstrated changes in their cancer tissue that may indicate reduced cancer aggression. This is according to research published in the journal Cancer Prevention Research.Prostate cancer is the most common cancer among American men.
Fish Oil May Hold Promise for Prostate Cancer (CME/CE)
Source: MedPage Today Oncology/Hematology [2013.11.20]
(MedPage Today) -- Prostate cancer patients who consumed a low-fat, high fish oil diet had significantly less tissue inflammation and proliferation than men who ate a typical Western diet, investigators reported.
Clinical predictors of acute urinary symptoms after radiotherapy for prostate cancer
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2013.11.19]
An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy.
Published Studies Related to Trelstar Depot (Triptorelin)
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. [2011.07.20]
CONTEXT: Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. OBJECTIVE: To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy... CONCLUSION: The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00311636.
A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. [2011.07]
PURPOSE: To compare the role of an aromatase inhibitor (letrozole) with a GnRH agonist (triptorelin) versus case control on the pregnancy rate and recurrence of symptoms and signs in patients with endometriosis... CONCLUSION: Pregnancy rate and endometriosis recurrence rate are comparable among the 3 groups.
Synchronization of ovulation and fertility in weaned sows treated with intravaginal triptorelin is influenced by timing of administration and follicle size. [2011.01.15]
A 100 mug dose of triptorelin was tested for synchronizing ovulation in sows. In Experiment 1, conducted in April through June, sows (n = 125) were assigned to Control (untreated), TG-96 (Triptorelin Gel (TG) given intravaginally at 96 h post-weaning), or TG-E (given intravaginally at estrus)... However, ovulation induction and timed AI success may benefit from an approach that ensures sows have adequate follicle development at time of treatment.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2010.01]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2009.01.08]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor may be advantageous for short-term management of women with myomas of any size who are to be managed transiently and who wish to avoid surgical intervention, specifically women with unexplained infertility having uterine myoma.
Clinical Trials Related to Trelstar Depot (Triptorelin)
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg [Recruiting]
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin
pamoate (Pamorelin® LA 11. 25 mg), applied either IM or SC, in terms of the area under the
curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer.
Study to Assess the Non-Inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT) [Recruiting]
The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for
a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH). GnRH is
a hormone secreted by hypothalamus (a gland located in brain) and controls the production of
sex hormones (eg testosterone in men) in other organs in the body. The growth of prostate
cancer cells, one of the most common cancers in men, is induced by the hormone testosterone.
Hormono-therapy is one of treatments available to treat this type of disease by controlling
the testosterone serum level. Pamorelin® 11,25 mg is normally injected in the muscle but
this type of injection is not suitable for every patient. Therefore the primary purpose of
this study is to assess the non-inferiority of the 12-week triptorelin formulation PamorelinÂ®
11,25 mg administered via subcutaneous (SC) injection as compared to PamorelinÂ® 11,25 mg
administered via standard intramuscular (IM) injection based on the percentage of patients
presenting a testosterone level â‰¤ 50 ng/dl at week 24.
Efficacy, Safety, and PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty [Recruiting]
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22. 5 mg
6-month formulation in 44 patients suffering from central precocious puberty. The null
hypothesis of the study is that the proportion of patients achieving LH suppression to
prepubertal levels at Month 6 is 80%.
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. [Recruiting]
The HOBOE study was amended in November 2009, and, after reaching enrollment of the first
500 patients, the study began recruiting premenopausal patients only. The primary objective
of the extended study is to compare disease free survival in premenopausal patients with
early breast cancer. Patients receive triptorelin and are randomized in a 1: 1:1 fashion to
receive tamoxifen or letrozole, or letrozole + zoledronic acid.
The purpose of the HOBOE study, Version 1, was to compare the adjuvant hormonal therapy
treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate for their effects on bone
loss in breast cancer patients. Postmenopausal and premenopausal patients were eligible, the
latter also receiving monthly triptorelin. Upon reaching the enrollment of the first 500
patients in March 2010, the study began recruiting premenopausal patients only.
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer [Recruiting]
The study will investigate the efficacy, pharmacokinetics and safety of triptorelin embonate
22. 5 mg 6-month formulation administered by subcutaneous injections in patients with